Table 1 Demographic, clinical and serological features at baseline
Demographic features | Value |
|---|---|
Female gender, n (%) | 96 (89.7%) |
Caucasian, (%) | 107 (100%) |
Onset age, median (IQR) years | 31.3 (25.0–42.6) |
Age at diagnosis, median (IQR) years | 34.3 (26.5–43.7) |
Disease duration at diagnosis, median (IQR) months | 9.7 (6.0–27.6) |
ACR 1997 clinical criteria | |
Malar rash, n (%) | 29 (27.1%) |
Discoid rash, n (%) | 7 (6.5%) |
Photosensitivity, n (%) | 26 (24.3%) |
Oral ulcers, n (%) | 11 (10.3%) |
Arthritis, n (%) | 96 (89.7%) |
Serositis, n (%) | 32 (29.9%) |
Renal disorders, n (%) | 27 (25.2%) |
Class Va | 4 (3.7%) |
Class IVa | 8 (7.5%) |
Class IIIa | 6 (5.6%) |
Class IIa | 3 (2.8%) |
Not biopsy proven | 6 (5.6%) |
Neurologic disorders, n (%) | 3 (2.8%) |
Haematological disorders, n (%) | 61 (57.0%) |
Disease activity | |
SLEDAI-2K score, median (IQR) | 10.0 (8.0-15.8) |
SLICC Damage Index, median IQRb | 0 (0-0) |
Serological features | |
ANA, n (%) | 106 (99.1%) |
Anti-dsDNA, n (%) | 78 (72.9%) |
Anti-Sm, n (%) | 19 (17.8%) |
Anti-RNP, n (%) | 27 (25.2%) |
Anti-SSA, n (%) | 46 (43.0%) |
Anti-SSB, n (%) | 13 (12.1%) |
Any aPLs | 26 (24.3%) |
Treatment | |
PDN dose at T0, median (IQR) mg/day | 15.0 (6.5–26.9) |
PDN dose T0–T2, median (IQR) mg/day | 10.4 (5.7–18.2) |
Anti-malarial drug, n (%) | 67 (62.6%) |
Immunosuppressant drug, n (%) | 68 (63.5%) |
Methotrexate, n (%) | 24 (22.4%) |
Cyclophosphamide, n (%) | 21 (19.6%) |
Azathioprine, n (%) | 17 (15.9%) |
Cyclosporine A, n (%) | 5 (4.7%) |
Mycophenolate mofetil, n (%) | 2 (1.9%) |
Rituximab, n (%) | 1 (0.9%) |